Cited by 860Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentBone health and treatments

The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.

Open access

Eisenberger, Mario A., Blumenstein, Brent A., Crawford, E. David, Miller, Gary, McLeod, David G., Loehrer, Patrick J., Wilding, George, Sears, Kathy, Culkin, Daniel J., Thompson, Ian M., Bueschen, Anton J., Lowe, Bruce A.·1998·New England Journal of Medicine

DOI 10.1056/nejm199810083391504

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Combined androgen blockade for the treatment of metastatic prostate cancer consists of an antiandrogen drug plus castration. In a previous trial, we found that adding the antiandrogen flutamide to leuprolide acetate (a synthetic gonadotropin-releasing hormone that results in medical ablation of testicular function) significantly improved survival as compared with that achieved with placebo plus leuprolide acetate. In the current trial, we compared flutamide plus bilateral orchiectomy with placebo plus orchiectomy. METHODS: We randomly assigned patients who had never received antiandrogen therapy and who had distant metastases from adenocarcinoma of the prostate to treatment with bilateral orchiectomy and either flutamide or placebo. Patients were stratified according to the extent of disease and according to performance status. RESULTS: Of the 1387 patients who were enrolled in the trial, 700 were randomly assigned to the flutamide group and 687 to the placebo group. Overall, the incidence of toxic effects was minimal; the only notable differences between the groups were the greater rates of diarrhea and anemia with flutamide. There was no significant difference between the two groups in overall survival (P=0.14). The estimated risk of death (hazard ratio) for flutamide as compared with placebo was 0.91 (90 percent confidence interval, 0.81 to 1.01). Flutamide was not associated with enhanced benefit in patients with minimal disease. CONCLUSIONS: The addition of flutamide to bilateral orchiectomy does not result in a clinically meaningful improvement in survival among patients with metastatic prostate cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm199810083391504

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Studies on Prostatic Cancer: I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate
Huggins, C., & Hodges, C. V. (2002) · The Journal of Urology · doi:10.1016/s0022-5347(05)64820-3 · Cited by 3,856
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Surrogate endpoints in clinical trials: Definition and operational criteria
Prentice, R. L. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080407 · Cited by 2,057
Cancer statistics, 1997
Parker, S. L., Tong, T., Bolden, S., & Wingo, P. A. (1997) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.47.1.5 · Cited by 2,000
A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma
Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., & Goodman, P. J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908173210702 · Cited by 1,464
Self-citation
Leuprolide versus Diethylstilbestrol for Metastatic Prostate Cancer
The Leuprolide Study Group (1984) · New England Journal of Medicine · doi:10.1056/nejm198411153112004 · Cited by 622
The veterans administration cooperative urological research group's studies of cancer of the prostate
Byar, D. P. (1973) · Cancer · doi:10.1002/1097-0142(197311)32:5 · Cited by 595
Designs for group sequential tests
Fleming, T. R., Harrington, D. P., & O’Brien, P. C. (1984) · Controlled Clinical Trials · doi:10.1016/s0197-2456(84)80014-8 · Cited by 354
Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients
Prostate Cancer Trialists' Collaborative Group (1995) · The Lancet · doi:10.1016/s0140-6736(95)92163-x · Cited by 320
Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation
Rubinstein, L., Gail, M. H., & Santner, T. J. (1981) · Journal of Chronic Diseases · doi:10.1016/0021-9681(81)90007-2 · Cited by 270

Show all 25 references

Research works printed but not linked: 3

Huggins C, 1941, Cancer Res, 1, 293
10.1002/1097-0142(19931215)72:12+<3834::AID-CNCR2820721714>3.0.CO;2-Z · DOI
Eisenberger MA, 1994, Semin Oncol, 21, 613

Sorted by citations

Items 101–200 of 860

COMPLETE ANDROGEN BLOCKADE FOR PROSTATE CANCER: WHAT WENT WRONG?
Laufer, M., Denmeade, S. R., Sinibaldi, V. J., Carducci, M. A., & Eisenberger, M. A. (2000) · The Journal of Urology · doi:10.1016/s0022-5347(05)67436-8 · Cited by 116
Self-citation
Prostate cancer stem cells: deciphering the origins and pathways involved in prostate tumorigenesis and aggression
Rybak, A. P., Bristow, R. G., & Kapoor, A. (2014) · Oncotarget · doi:10.18632/oncotarget.2953 · Cited by 122
Modulation of androgen receptor transactivation by gelsolin: a newly identified androgen receptor coregulator.
Nishimura, K., Ting, H., Harada, Y., Tokizane, T., Nonomura, N., Kang, H., Chang, H., Yeh, S., Miyamoto, H., Shin, M., et al. (2003) · PubMed · Cited by 115
Endocrine treatment of prostate cancer
Tammela, T. L. J. (2004) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2004.10.005 · Cited by 113
Adjuvant Androgen Deprivation for High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 Study
Dorff, T. B., Flaig, T. W., Tangen, C. M., Hussain, M., Swanson, G. P., Wood, D. P., Sakr, W., Dawson, N. A., Haas, N. B., Crawford, E. D., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2776 · Cited by 112
Self-citation
Castration-Resistant Prostate Cancer: Mechanisms, Targets, and Treatment
Amaral, T. M. S., Macedo, D., Fernandes, I., & Costa, L. (2012) · Prostate Cancer · doi:10.1155/2012/327253 · Cited by 117
A retrospective study of the time to clinical endpoints for advanced prostate cancer
Sharifi, N., Dahut, W. L., Steinberg, S. M., Figg, W. D., Tarassoff, C. P., Arlen, P. M., & Gulley, J. L. (2005) · British Journal of Urology · doi:10.1111/j.1464-410x.2005.05798.x · Cited by 111
Is Prostate-Specific Antigen a Valid Surrogate End Point for Survival in Hormonally Treated Patients With Metastatic Prostate Cancer? Joint Research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals
Collette, L., Burzykowski, T., Carroll, K. J., Newling, D. W. W., Morris, T., & Schröder, F. H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.156 · Cited by 111
A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC)
Harrison, M. R., Hahn, N. M., Пили, Р., Oh, W. K., Hammers, H. J., Sweeney, C. J., Kim, K., Perlman, S. B., Arnott, J., Sidor, C. F., et al. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9455-x · Cited by 110
Self-citation
Recommandations en onco-urologie 2016-2018 du CCAFU : Cancer de la prostate
Rozet, F., Hennequin, C., Beauval, J., Beuzeboc, P., Cormier, L., Fromont, G., Mongiat-Artus, P., Ouzzane, A., Ploussard, G., Azria, D., et al. (2016) · The French Journal of Urology · doi:10.1016/s1166-7087(16)30705-9 · Cited by 114
Castration-recurrent prostate cancer is not androgen-independent.
Mohler, J. L. (2008) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-69080-3_21 · Cited by 106
Reciprocal regulation of GAS5 lncRNA levels and mTOR inhibitor action in prostate cancer cells
Yacqub‐Usman, K., Pickard, M. R., & Williams, G. T. (2015) · The Prostate · doi:10.1002/pros.22952 · Cited by 105
A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth In Vitro and In Vivo
Kuruma, H., Matsumoto, H., Shiota, M., Bishop, J. L., Lamoureux, F., Thomas, C., Briere, D. M., Los, G., Gleave, M. E., Fanjul, A. N., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0798 · Cited by 105
Clinical implications of neuroendocrine differentiation in prostate cancer
Nelson, E. C., Cambio, A., Yang, J. C., Ok, J.-H., Lara, P. N., & Evans, C. P. (2006) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500922 · Cited by 103
Overview: hormone refractory prostate cancer
Crawford, E. D., Rosenblum, M., Ziada, A. M., & Lange, P. H. (1999) · Urology · doi:10.1016/s0090-4295(99)00447-1 · Cited by 102
Self-citation
Improved Overall Survival Trends of Men with Newly Diagnosed M1 Prostate Cancer: A SWOG Phase III Trial Experience (S8494, S8894 and S9346)
Tangen, C. M., Hussain, M., Higano, C. S., Eisenberger, M. A., Small, E. J., Wilding, G., Donnelly, B. J., Schelhammer, P. F., Crawford, E. D., Vogelzang, N. J., et al. (2012) · The Journal of Urology · doi:10.1016/j.juro.2012.06.046 · Cited by 101
Self-citation
Maximal androgen blockade for advanced prostate cancer
Schmitt, B. P., Bennett, C. L., Seidenfeld, J., Samson, D. J., & Wilt, T. J. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001526 · Cited by 101
Testosterone Surge: Rationale for Gonadotropin-Releasing Hormone Blockers?
Poppel, H. V., & Nilsson, S. F. (2008) · Urology · doi:10.1016/j.urology.2007.12.070 · Cited by 101
Adverse Effects of Androgen Deprivation Therapy: Defining the Problem and Promoting Health Among Men with Prostate Cancer
Saylor, P. J., & Smith, M. R. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0014 · Cited by 100
Prostate-Specific Antigen Nadir and Cancer-Specific Mortality Following Hormonal Therapy for Prostate-Specific Antigen Failure
Stewart, A., Scher, H. I., Chen, M., McLeod, D. G., Carroll, P. R., Moul, J. W., & D'Amico, A. V. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.20.966 · Cited by 100
Self-citation
Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi‐arm, multistage randomized controlled trial
James, N. D., Sydes, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Anderson, J., Popert, R., Sanders, K., Morgan, R. C., Stansfeld, J., et al. (2008) · British Journal of Urology · doi:10.1111/j.1464-410x.2008.08034.x · Cited by 99
Androgen blocks apoptosis of hormone-dependent prostate cancer cells.
Kimura, K., Markowski, M. C., Bowen, C., & Gelmann, E. P. (2001) · PubMed · Cited by 97
Impact of previous local treatment for prostate cancer on subsequent metastatic disease.
Thompson, I. M., Tangen, C. M., Basler, J. W., & Crawford, E. D. (2002) · PubMed · doi:10.1016/s0022-5347(05)64562-4 · Cited by 96
Self-citation
Emerging technology: applications of Raman spectroscopy for prostate cancer
Kast, R. E., Tucker, S. C., Killian, K., Trexler, M., Honn, K. V., & Auner, G. W. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9489-6 · Cited by 94
Immediate Versus Deferred Hormonal Treatment for Patients With Prostate Cancer Who Are Not Suitable for Curative Local Treatment: Results of the Randomized Trial SAKK 08/88
Studer, U. E., HAURI, D., Hanselmann, S., Chollet, D., Leisinger, H., Gasser, T., Senn, E., Trinkler, F. B., Tscholl, R., Thalmann, G. N., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.514 · Cited by 94
Effective testosterone suppression for prostate cancer: is there a best castration therapy?
Gomella, L. G. (2009) · Europe PMC (PubMed Central) · Cited by 92
Rising prostate-specific antigen after primary prostate cancer therapy
Ward, J. F., & Moul, J. W. (2005) · Nature Clinical Practice Urology · doi:10.1038/ncpuro0145 · Cited by 91
Pretreatment Neutrophil-to-Lymphocyte Ratio in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Ketoconazole: Association with Outcome and Predictive Nomogram
Keizman, D., Gottfried, M., Ish‐Shalom, M., Maimon, N., Peer, A., Neumann, A., Rosenbaum, E., Kovel, S., Пили, Р., Sinibaldi, V. J., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0125 · Cited by 90
Self-citation
Bicalutamide (Casodex®) in the treatment of prostate cancer
Fradet, Y. (2004) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.4.1.37 · Cited by 89
Blockade of testicular and adrenal androgens in prostate cancer treatment
Labrie, F. (2011) · Nature Reviews Urology · doi:10.1038/nrurol.2010.231 · Cited by 89
Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020 : cancer de la prostate
Rozet, F., Hennequin, C., Beauval, J., Beuzeboc, P., Cormier, L., Fromont, G., Mongiat-Artus, P., Ploussard, G., Mathiéu, R., Brureau, L., et al. (2018) · The French Journal of Urology · doi:10.1016/j.purol.2019.01.007 · Cited by 89
Quality of Life and Pain in Advanced Stage Prostate Cancer: Results of a Southwest Oncology Group Randomized Trial Comparing Docetaxel and Estramustine to Mitoxantrone and Prednisone
Berry, D. L., Moinpour, C. M., Jiang, C. S., Ankerst, D. P., Petrylak, D. P., Vinson, L. V., Lara, P. N., Jones, S., Taplin, M. E., Burch, P. A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.8207 · Cited by 88
Self-citation
Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial
Mottet, N., Damme, J. V., Loulidi, S., Rüssel, C., Leitenberger, A., Wolff, J. M., & the TAP22 Investigators Group (2012) · British Journal of Urology · doi:10.1111/j.1464-410x.2012.11120.x · Cited by 86
Stromal Androgen Receptor in Prostate Development and Cancer
Singh, M., Jha, R., Melamed, J., Shapiro, E., Hayward, S. W., & Lee, P. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.06.022 · Cited by 94
Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways
Vis, A. N., & Schröder, F. H. (2009) · British Journal of Urology · doi:10.1111/j.1464-410x.2009.08695.x · Cited by 86
Phase II Study of Androgen Synthesis Inhibition with Ketoconazole, Hydrocortisone, and Dutasteride in Asymptomatic Castration-Resistant Prostate Cancer
Taplin, M., Regan, M. M., Ko, Y., Bubley, G. J., Duggan, S., Werner, L. L., Beer, T. M., Ryan, C. W., Mathew, P. F., Tu, S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1722 · Cited by 83
Prostate cancer treated by anti-androgens: is sexual function preserved?
Schröder, F. H., Collette, L., de Reijke, T. M., & Whelan, P. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.0916 · Cited by 85
Ten-Year Survival in Patients with Metastatic Prostate Cancer
Tangen, C. M., Faulkner, J. R., Crawford, E. D., Thompson, I. M., Hirano, D., Eisenberger, M. A., & Hussain, M. (2003) · Clinical Prostate Cancer · doi:10.3816/cgc.2003.n.011 · Cited by 85
Self-citation
Silencing Notch-1 induces apoptosis and increases the chemosensitivity of prostate cancer cells to docetaxel through Bcl-2 and Bax
He, L.-Y. (2012) · Oncology Letters · doi:10.3892/ol.2012.572 · Cited by 84
Androgen deprivation therapy for prostate cancer
Singer, E. A., Golijanin, D. J., Miyamoto, H., & Messing, E. M. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.2.211 · Cited by 84
A re‐assessment of the role of combined androgen blockade for advanced prostate cancer
Klotz, L. H., Schellhammer, P. E., & Carroll, K. (2004) · British Journal of Urology · doi:10.1111/j.1464-410x.2004.04803.x · Cited by 84
Long‐term overall survival and metastasis‐free survival for men with prostate‐specific antigen‐recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database
Antonarakis, E. S., Chen, Y., Elsamanoudi, S. I., Brassell, S. A., Rocha, M. V. D., Eisenberger, M. A., & McLeod, D. G. (2010) · British Journal of Urology · doi:10.1111/j.1464-410x.2010.09878.x · Cited by 83
Self-citation
PSA Progression Following Radical Prostatectomy and Radiation Therapy: New Standards in the New Millenium
Djavan, B., Moul, J. W., Zlotta, A. R., Mesut Remzi, A., & Ravery, V. V. (2002) · European Urology · doi:10.1016/s0302-2838(02)00505-5 · Cited by 83
Value of Information and Value of Implementation: Application of an Analytic Framework to Inform Resource Allocation Decisions in Metastatic Hormone-Refractory Prostate Cancer
Hoomans, T., Fenwick, E. A. L., Palmer, S., & Claxton, K. (2008) · Value in Health · doi:10.1111/j.1524-4733.2008.00431.x · Cited by 82
Inhibition effects and induction of apoptosis of flavonoids on the prostate cancer cell line PC-3 in vitro
Xu, R., Zhang, Y., Ye, X., Xue, S. J., Shi, J., Pan, J., & Chen, Q. (2012) · Food Chemistry · doi:10.1016/j.foodchem.2012.09.102 · Cited by 82
CYP17A1 inhibitors in castration-resistant prostate cancer
Gomez, L., Kovac, J. R., & Lamb, D. J. (2015) · Steroids · doi:10.1016/j.steroids.2014.12.021 · Cited by 84
Markers and meaning of primary treatment failure
Swindle, P., Kattan, M. W., & Scardino, P. T. (2003) · Urologic Clinics of North America · doi:10.1016/s0094-0143(02)00176-3 · Cited by 82
Naringin sensitizes human prostate cancer cells to paclitaxel therapy
Erdoğan, S., Doğanlar, O., Doğanlar, Z. B., & Turkekul, K. (2017) · Prostate International · doi:10.1016/j.prnil.2017.11.001 · Cited by 80
Cancer de la prostate
Beuzeboc, P., Cornud, F., Eschwège, P., Gaschignard, N., Grosclaude, P., Hennequin, C., Maingon, P., Molinié, V., Mongiat-Artus, P., Moreau, J.-L., et al. (2007) · The French Journal of Urology · doi:10.1016/s1166-7087(07)74785-1 · Cited by 80
Sipuleucel-T: A Vaccine for Metastatic, Asymptomatic, Androgen-Independent Prostate Cancer
Patel, P. H., & Kockler, D. R. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1k429 · Cited by 80
MANAGEMENT OF LOCALLY ADVANCED PROSTATE CANCER: A EUROPEAN CONSENSUS
BOCCON-GIBOD, L., Bertaccini, A., Bono, A., Sarmah, B., HÖLTL, W., Mottet, N., Tunn, U. W., & Zamboglou, N. (2003) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2003.tb10462.x · Cited by 80
Switching and withdrawing hormonal agents for castration-resistant prostate cancer
Lorente, D., Mateo, J., Zafeiriou, Z., Smith, A. D., Sandhu, S. K., Ferraldeschi, R., & Bono, J. S. D. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2014.345 · Cited by 79
Progress in Understanding Androgen-Independent Prostate Cancer (AIPC): A Review of Potential Endocrine-Mediated Mechanisms
Schröder, F. H. (2008) · European Urology · doi:10.1016/j.eururo.2008.01.049 · Cited by 78
Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials
Collette, L., Burzykowski, T., & Schröder, F. H. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.02.011 · Cited by 78
Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone‐sensitive prostate cancer
Shiota, M., & Eto, M. (2016) · International Journal of Urology · doi:10.1111/iju.13091 · Cited by 78
Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality
Hedlund, P. O., & Henriksson, P. (2000) · Urology · doi:10.1016/s0090-4295(99)00580-4 · Cited by 78
Localised delivery of doxorubicin to prostate cancer cells through a PSMA-targeted hyperbranched polymer theranostic
Pearce, A. K., Simpson, J. D., Fletcher, N. L., Houston, Z. H., Fuchs, A. V., Russell, P. J., Whittaker, A. K., & Thurecht, K. J. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.07.004 · Cited by 76
Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer
Cattrini, C., Castro, E., Mejorada, R. L., Zanardi, E., RUBAGOTTI, A., Boccardo, F., & Olmos, D. (2019) · Cancers · doi:10.3390/cancers11091355 · Cited by 81
Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment
Wang, Y., Nangia‐Makker, P., Balan, V., Hogan, V. A., & Raz, A. (2010) · Cell Death and Disease · doi:10.1038/cddis.2010.79 · Cited by 77
Dysregulated microRNA-224/apelin axis associated with aggressive progression and poor prognosis in patients with prostate cancer
Wan, Y., Zeng, Z.-C., Xi, M., Song, W., Hua, W., Liu, Y., Zhou, Y., Luo, H., Jiang, F., & Zhong, W. (2014) · Human Pathology · doi:10.1016/j.humpath.2014.10.027 · Cited by 77
Current Indications for Chemotherapy in Prostate Cancer Patients
Calabrò, F., & Sternberg, C. N. (2006) · European Urology · doi:10.1016/j.eururo.2006.08.013 · Cited by 77
Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells.
Weeraratna, A. T., Dalrymple, S. L., Lamb, J. C., Denmeade, S. R., Miknyoczki, S. J., Dionne, C. A., & Isaacs, J. T. (2001) · PubMed · Cited by 77
New Developments in the Medical Management of Prostate Cancer
Kohli, M., & Tindall, D. J. (2009) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0442 · Cited by 76
The Transcriptional Co-Activator cAMP Response Element-Binding Protein-Binding Protein Is Expressed in Prostate Cancer and Enhances Androgen- and Anti-Androgen-Induced Androgen Receptor Function
Comuzzi, B., Lambrinidis, L., Rogatsch, H., Godoy‐Tundidor, S., Knežević, N., Krhen, I., Mareković, Z., Bartsch, G. H., Klocker, H., Hobisch, A., et al. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63814-x · Cited by 76
Targeted therapeutic approaches for hormone-refractory prostate cancer
Stavridi, F., Karapanagiotou, E. M., & Syrigos, K. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.06.001 · Cited by 75
Parkinson’s disease influences the perioperative risk profile in surgery
Mueller, M., Jüptner, U., Wüllner, U., Wirz, S., Türler, A., Hirner, A., & Standop, J. (2008) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-008-0404-5 · Cited by 73
Intermittent Androgen Deprivation Therapy for Prostate Cancer
Rashid, M. H., & Chaudhary, U. B. (2004) · The Oncologist · doi:10.1634/theoncologist.9-3-295 · Cited by 72
Indium-111 capromab pendetide in the management of recurrent prostate cancer
Manyak, M. J. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.2.175 · Cited by 70
Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC)
Nicolini, A., Pa, M., Ferrari, P., Anselmi, L., Tartarelli, G., Bonazzi, V., Carpi, A., & Giardino, R. (2004) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2004.08.006 · Cited by 71
Targeting 5α-reductase for prostate cancer prevention and treatment
Nacusi, L. P., & Tindall, D. J. (2011) · Nature Reviews Urology · doi:10.1038/nrurol.2011.67 · Cited by 69
Impact of prostate‐specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen‐deprivation therapy
Huang, S., Bao, B., Wu, M., Choueiri, T. K., Goggins, W. B., Huang, C., Pu, Y., Yu, C., & Huang, C. (2011) · The Prostate · doi:10.1002/pros.21334 · Cited by 69
Overexpression of LLT1 (OCIL, CLEC2D) on prostate cancer cells inhibits NK cell-mediated killing through LLT1-NKRP1A (CD161) interaction
Mathew, S. O., Chaudhary, P., Powers, S. B., Vishwanatha, J. K., & Mathew, P. A. (2016) · Oncotarget · doi:10.18632/oncotarget.11896 · Cited by 69
Health related quality of life in prostate carcinoma patients
Efficace, F., Bottomley, A., & van Andel, G. (2003) · Cancer · doi:10.1002/cncr.11065 · Cited by 68
An index of local sensitivity to nonignorable drop-out in longitudinal modelling
Ma, G., Troxel, A. B., & Heitjan, D. F. (2005) · Statistics in Medicine · doi:10.1002/sim.2107 · Cited by 67
Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
Rodríguez‐Vida, A., Chowdhury, S., Sternberg, C. N., Rudman, S. M., & Galazi, M. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s69433 · Cited by 69
The role of prostate specific antigen measurement in the detection and management of prostate cancer.
Nash, A., & Melezínek, I. (2000) · Endocrine Related Cancer · doi:10.1677/erc.0.0070037 · Cited by 66
Human epidermal receptor-2 expression in prostate cancer.
Calvo, B. F., LEVINE, A. M., Marcos, M., Collins, Q. F., Iacocca, M., Caskey, L. S., Gregory, C. W., Lin, Y., Whang, Y. E., Earp, H. S., et al. (2003) · PubMed · Cited by 66
Failure to Maintain a Suppressed Level of Serum Testosterone during Long-Acting Depot Luteinizing Hormone-Releasing Hormone Agonist Therapy in Patients with Advanced Prostate Cancer
Moróte, J., Esquena, S., Junquera, J. M. A., Trilla, E., Cecchini, L., Raventos, C. X., Catalán, R., & Reventós, J. (2006) · Urologia Internationalis · doi:10.1159/000093907 · Cited by 65
Prostate Cancer Survivorship: Prevention and Treatment of the Adverse Effects of Androgen Deprivation Therapy
Saylor, P. J., Keating, N. L., & Smith, M. R. (2009) · Journal of General Internal Medicine · doi:10.1007/s11606-009-0968-y · Cited by 65
SOXs in human prostate cancer: implication as progression and prognosis factors
Zhong, W., Qin, G., Dai, Q.-S., Han, Z., Chen, S.-M., Ling, X., Fu, X., Cai, C., Chen, J.-H., Chen, X.-B., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-248 · Cited by 65
Antiandrogens in Prostate Cancer
Reid, P., Kantoff, P. W., & Oh, W. K. (1999) · Investigational New Drugs · doi:10.1023/a:1006344807086 · Cited by 65
Development of a polymer theranostic for prostate cancer
Pearce, A. K., Rolfe, B. E., Russell, P. J., Tse, B. W.-C., Whittaker, A. K., Fuchs, A. V., & Thurecht, K. J. (2014) · Polymer Chemistry · doi:10.1039/c4py00999a · Cited by 64
Positron emission tomography imaging of prostate cancer
Hong, H., Zhang, Y., Sun, J., & Cai, W. (2009) · Amino Acids · doi:10.1007/s00726-009-0394-9 · Cited by 63
The PTEN tumor suppressor is a negative modulator of androgen receptor transcriptional activity
Nan, B., Snabboon, T., Unni, E., X-J, Y., Whang, Y. E., & Marcelli, M. (2003) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0310169 · Cited by 63
Hematological changes during androgen deprivation therapy
Grossmann, M., & Zajac, J. D. (2012) · Asian Journal of Andrology · doi:10.1038/aja.2011.102 · Cited by 62
Risk of Prostate Cancer Recurrence in Men Treated With Radiation Alone or in Conjunction With Combined or Less Than Combined Androgen Suppression Therapy
D'Amico, A. V., Chen, M., Renshaw, A. A., Loffredo, B., & Kantoff, P. W. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9699 · Cited by 62
Synergistic Local Combination of Radiation and Anti-Programmed Death Ligand 1 Immunotherapy Using Radiation-Responsive Splintery Metallic Nanocarriers
Choi, B., Choi, H., Yu, B., & Kim, D. (2020) · ACS Nano · doi:10.1021/acsnano.0c04701 · Cited by 63
Evidence-based estimate of appropriate radiotherapy utilization rate for prostate cancer
Foroudi, F., Tyldesley, S. K., Barbera, L. C., Huang, J., & Mackillop, W. J. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)03866-x · Cited by 62
Pre-Treatment Nomogram for Disease-Specific Survival of Patients with Chemotherapy-Naive Androgen Independent Prostate Cancer
Svatek, R. S., Karakiewicz, P. I., Shulman, M. J., Karam, J. A., Perrotte, P., & Benaim, E. A. (2006) · European Urology · doi:10.1016/j.eururo.2005.11.032 · Cited by 61
Newly Developed Targeted Therapies Against the Androgen Receptor in Triple-Negative Breast Cancer: A Review
Choupani, E., Gomari, M. M., Zanganeh, S., Nasseri, S., Haji-Allahverdipoor, K., Rostami, N., Hernandez, Y., Najafi, S., Saraygord‐Afshari, N., & Hosseini, A. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000665 · Cited by 61
A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer
Sharifi, N., Hamada, A., Sissung, T. M., Danesi, R., Venzon, D. J., Baum, C. E., Gulley, J. L., Price, D. K., Dahut, W. L., & Figg, W. D. (2008) · British Journal of Urology · doi:10.1111/j.1464-410x.2008.07629.x · Cited by 60
Combined androgen blockade for prostate cancer: Review of efficacy, safety and cost‐effectiveness
Akaza, H. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01774.x · Cited by 60
Decreased expression of myosin light chain MYL9 in stroma predicts malignant progression and poor biochemical recurrence-free survival in prostate cancer
Huang, Y., Han, Z., Liang, Y., Lin, Z., Ling, X., Fu, X., Cai, C., Bi, X., Dai, Q.-S., Chen, J.-H., et al. (2013) · Medical Oncology · doi:10.1007/s12032-013-0820-4 · Cited by 60
Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project
Lord, J. L., Willis, S., Eatock, J., Tappenden, P., Trapero‐Bertran, M., Miners, A. H., Crossan, C., Westby, M. J., Anagnostou, A., Taylor, S. J. E., et al. (2013) · Health Technology Assessment · doi:10.3310/hta17580 · Cited by 61
Androgen receptor: role and novel therapeutic prospects in prostate cancer
Taplin, M. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.9.1495 · Cited by 60
Metabolomic Profiling Identifies Biochemical Pathways Associated with Castration-Resistant Prostate Cancer
Kaushik, A., Vareed, S. K., Basu, S., Putluri, V., Putluri, N., Panzitt, K., Brennan, C. A., Chinnaiyan, A. M., Vergara, I. A., Erho, N., et al. (2013) · Journal of Proteome Research · doi:10.1021/pr401106h · Cited by 59
Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer
Xia, Y. F., Huang, C., Dittmar, R. L., Du, M., Wang, Y., Liu, H., Shenoy, N. K., Wang, L., & Kohli, M. (2016) · Oncotarget · doi:10.18632/oncotarget.9027 · Cited by 59
Androgen deprivation therapy-induced epithelial-mesenchymal transition of prostate cancer through downregulating SPDEF and activating CCL2
Tsai, Y.-C., Chen, W., Abou-Kheir, W. G., Zeng, T., Yin, J. J., Bahmad, H. F., Lee, Y., & Liu, Y. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.02.016 · Cited by 60
Treatment of Localized Prostate Cancer With Intermittent Triple Androgen Blockade: Preliminary Results in 110 Consecutive Patients
Leibowitz, R. L., & Tucker, S. J. (2001) · The Oncologist · doi:10.1634/theoncologist.6-2-177 · Cited by 59
Isorhamnetin inhibited the proliferation and metastasis of androgen-independent prostate cancer cells by targeting the mitochondrion-dependent intrinsic apoptotic and PI3K/Akt/mTOR pathway
Cai, F., Zhang, Y., Li, J., Huang, S., & Gao, R. (2020) · Bioscience Reports · doi:10.1042/bsr20192826 · Cited by 58

Authors: Eisenberger, M. A., Blumenstein, B. A., Crawford, E. D., Miller, G., McLeod, D. G., Loehrer, P. J., Wilding, G., Sears, K., Culkin, D. J., Thompson, I. M., Bueschen, A. J., & Lowe, B. A.
Affiliations: Johns Hopkins Hospital (US)
SWOG Cancer Research Network (US)
University of Colorado Denver (US)
Walter Reed National Military Medical Center (US)
University of Wisconsin–Madison (US)
University of Oklahoma Health Sciences Center (US)
University of Alabama at Birmingham (US)
Oregon Health & Science University (US)
ORCID: Eisenberger, Mario A.
Blumenstein, Brent A.
Crawford, E. David
McLeod, David G.
Loehrer, Patrick J.
Wilding, George
Culkin, Daniel J.
Thompson, Ian M.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1998-10-08
Volume: 339
Issue: 15
Pages: 1036-1042
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199810083391504
OpenAlex: W2003985632
Cited by: 859
References: 25
Citations by year: 2026: 2 · 2025: 5 · 2024: 8 · 2023: 12 · 2022: 20 · 2021: 15 · 2020: 21 · 2019: 26 · 2018: 25 · 2017: 23 · 2016: 34 · 2015: 52 · 2014: 49 · 2013: 51 · 2012: 37
FWCI: 37.16
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (2u10ca038926-25)
National Cancer Institute (CA-32102, CA 42777, U10CA032102, U10CA042777, CA 38926)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Bone health and treatments
Keywords: metastatic prostate cancer, bilateral orchiectomy, flutamide, combined androgen blockade, leuprolide, antiandrogen therapy, overall survival, adverse effects, anemia, diarrhea
MeSH terms: Adenocarcinoma, Adult, Aged, Aged, 80 and over, Androgen Antagonists, Bone Neoplasms, Combined Modality Therapy, Double-Blind Method, Flutamide, Humans, Male, Middle Aged, Orchiectomy, Prostatic Neoplasms, Soft Tissue Neoplasms, Survival Analysis, Prostate-Specific Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks